Core Insights - Scinai Immunotherapeutics Ltd. has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, aiming to enhance the clinical development of its IL-17 program and VHH antibody pipeline [1][5] Company Overview - Scinai Immunotherapeutics is a biopharmaceutical company focused on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices unit [5] - The company has a pipeline of nanosized VHH antibodies targeting diseases with significant unmet medical needs [5] Dr. Jonathan Sadeh's Background - Dr. Sadeh has over 20 years of experience in drug development and clinical research, previously holding senior positions at Bristol-Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough [2][3] - He was responsible for multiple drug approvals, including the first-in-class TYK2 inhibitor Sotyktu for psoriasis [2] Strategic Importance - Dr. Sadeh's expertise is expected to be invaluable for advancing Scinai's innovative I&I biological products [5] - His commitment to developing therapies for unmet medical needs aligns with Scinai's mission to establish itself as a leader in scientifically driven drug development [4][5]
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board